Hengrui Announces Drug Inclusions in China’s 2026 NRDLTip Ranks·Nov 15, 2026 at 11:07 AM01276-1.20%600276+0.29%
BeOne Medicines Ltd (6160) Gets a Buy from DaiwaTip Ranks·Nov 11, 2026 at 01:05 AMONC+0.14%06160-2.35%
Tigermed plans to sell Frontage's overseas laboratory business to Charles River, Song LiPUBT·Nov 10, 2026 at 09:53 AMCRL-0.83%01521-0.48%
Citi: Removal of WUXI APPTEC from US 1260H List a Major PositiveAASTOCKS News·Nov 10, 2026 at 04:55 AM02359-4.87%603259-2.69%
Nomura Positive on WUXI APPTEC Outlook at Investor Day, Maintains Buy RatingAASTOCKS News·Nov 9, 2026 at 04:01 AM02359-4.87%603259-2.69%
G Sachs: Strong 3Q Orders for China's CRO and CDMO Firms Enhance Visibility for 2027AASTOCKS News·Nov 12, 2026 at 07:05 AM02359-4.87%03347-3.21%
A-Share Three Major Indices Open 0.6%-2.4% Higher; APPTEC Gains Over 4%, ZHONGJI INNOLIGHT Jumps 6%AASTOCKS News·Nov 10, 2026 at 01:50 AM02359-4.87%03308-9.39%
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 | BRVE Stock NewsStockTitan·Nov 6, 2026 at 12:15 PMBRVE-4.29%01276-1.20%
Missed WuXi AppTec's Rally? Here's What Early Buyers SawSimplywall·Nov 9, 2026 at 12:43 PM02359-4.87%603259-2.69%
Citi Adds WUXI APPTEC to 90-Day Positive Catalyst Watch on Easing Geopolitical ConcernsAASTOCKS News·Nov 11, 2026 at 03:15 AM02359-4.87%603259-2.69%
Morgan Stanley Sticks to Their Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)Tip Ranks·Nov 5, 2026 at 12:27 AM03759-5.89%300759-3.92%
HSBC Research Raises WUXI APPTEC TP to HKD225.9, Quarterly Results Beat Forecasts for 3 Consecutive QuartersAASTOCKS News·Nov 2, 2026 at 06:33 AM02359-4.87%603259-2.69%
Jiangsu Hengrui Appoints Zhang Wei as Senior Vice PresidentPUBT·Nov 3, 2026 at 09:04 AM01276-1.20%600276+0.29%
HSI Closes Midday at 23,529, Up 3 pts; HSTI Closes Midday at 3,828, Down 39 pts; WUXI APPTEC Up over 5%; MENGNIU DAIRY Hit New HighsAASTOCKS News·Nov 4, 2026 at 04:18 AM01196-0.45%02319+0.74%
JPM: China's CDMO Sector Enters New Development Phase; Initiates Overweight on PHARMARON and ASYMCHEM H ShrsAASTOCKS News·Nov 6, 2026 at 07:03 AM03759-5.89%06821-5.42%
